oxytetracycline--anhydrous and Cleft-Palate

To evaluate the possible association between all kinds of drug treatments during pregnancy and isolated cleft lip with or without cleft palate (CL/P) and posterior cleft palate (PCP) in the offspring.. The dataset of the large population-based Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996, was evaluated.. One thousand three hundred seventy-four cases with isolated CL/P and 601 with PCP, plus 38,151 population controls (without birth defects) and 20,868 malformed controls with other defects.. In this observation case-control study the data collection was based on prospective medical records particularly prenatal logbook, retrospective maternal data via a self-reported questionnaire, and home visits of nonresponding mothers.. Isolated CL/P and PCP associated with drug treatments during pregnancy.. An increased risk for isolated CL/P was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and thiethylperazine during the second and third month of pregnancy, i.e., the critical period of isolated CL/P. Risk of isolated PCP was increased in mothers with oxytetracycline and carbamazepine treatment during the third and fourth month of pregnancy, i.e., the critical period of PCP.. This study confirmed the orofacial cleft (OFC) inducing effect of phenytoin, carbamazepine, oxytetracycline, and thiethylperazine and suggested a possible association between OFCs and oxprenolol and amoxicillin. However, drugs may have only a limited role in the origin of isolated OFCs.

Topics: Abnormalities, Drug-Induced; Adrenergic beta-Antagonists; Amoxicillin; Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Case-Control Studies; Cleft Lip; Cleft Palate; Dopamine Antagonists; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hungary; Oxprenolol; Oxytetracycline; Phenytoin; Population Surveillance; Pregnancy; Pregnancy Trimesters; Prospective Studies; Retrospective Studies; Risk Factors; Thiethylperazine

To study human teratogenic potential of oral oxytetracycline treatment during pregnancy.. The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996.. Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations.. Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus.

Topics: Abnormalities, Drug-Induced; Adult; Anti-Bacterial Agents; Case-Control Studies; Cleft Palate; Female; Heart Defects, Congenital; Humans; Hungary; Hypospadias; Logistic Models; Male; Neural Tube Defects; Oxytetracycline; Population Surveillance; Pregnancy; Pregnancy Complications; Risk Assessment

Topics: Anti-Bacterial Agents; Child, Preschool; Chloramphenicol; Cleft Lip; Cleft Palate; Cross Infection; Enterobacter; Escherichia coli; Humans; Mouth; Oxytetracycline; Penicillins; Staphylococcus; Streptococcus; Streptococcus pneumoniae; Streptomycin; Surgical Wound Infection